Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.

Dubey S, Jänne PA, Krug L, Pang H, Wang X, Heinze R, Watt C, Crawford J, Kratzke R, Vokes E, Kindler HL. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010 Oct; 5(10):1655-61.

View in: PubMed

collapse authors with profiles